Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The effective treatment of cancer by immunotherapy requires the induction of high numbers of tumor-specific type-1 polarized T cells. Since DCs are the key antigen-presenting cells capable of activating and polarizing T cells, the generation of type-1 polarized DCs for DC-based anti-cancer therapies is desired. We have previously shown that DCs matured with calcium ionophore (CI) alone results in the generation of type-2 polarized DCs, which lack IL-12 production. However, we now show that pre-treatment of monocyte-derived DCs with CI followed by the maturation with the inflammatory cytokine IFNγ and the TLR agonists LPS (TLR2) and R848 (TLR7/8), results in an enhanced IL-12 production by the DCs compared to DCs matured without CI pre-treatment. The effect of CI on IL-12 production appears to be dependent on the kinetics of CI pre-treatment as well as on the maturation factors used following CI addition. The CI-matured DCs show a more mature phenotype (based on CD83 and CCR7 expression), express higher levels of the co-stimulatory molecule CD70, and have reduced expression of the inhibitory molecule PD-L1 compared to DCs matured without CI-pre-treatment. When loaded with antigen these CI-matured DCs strongly induce T cell proliferation and the expression of the cytolytic proteins granzyme B and perforin by CD8+ T cells in a mixed leukocyte reaction. The ability of CI to induce type-1 polarization with enhanced IL-12 secretion and T cell stimulatory function allows for the development of type-1 polarized DC-based anti-cancer vaccines.